CR7387A - Nuevos compuestos heterociclicos activos como inhibidores de las beta- lactamasas - Google Patents

Nuevos compuestos heterociclicos activos como inhibidores de las beta- lactamasas

Info

Publication number
CR7387A
CR7387A CR7387A CR7387A CR7387A CR 7387 A CR7387 A CR 7387A CR 7387 A CR7387 A CR 7387A CR 7387 A CR7387 A CR 7387A CR 7387 A CR7387 A CR 7387A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
lactamasas
beta
new active
heterociclic compounds
Prior art date
Application number
CR7387A
Other languages
English (en)
Spanish (es)
Inventor
Jozsef Aszodi
Claude Fromentin
Maxime Lampilas
David Alan Rowlands
Original Assignee
Novexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR7387(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novexel filed Critical Novexel
Publication of CR7387A publication Critical patent/CR7387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR7387A 2002-01-28 2004-07-13 Nuevos compuestos heterociclicos activos como inhibidores de las beta- lactamasas CR7387A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (1)

Publication Number Publication Date
CR7387A true CR7387A (es) 2010-10-25

Family

ID=27619669

Family Applications (2)

Application Number Title Priority Date Filing Date
CR7387A CR7387A (es) 2002-01-28 2004-07-13 Nuevos compuestos heterociclicos activos como inhibidores de las beta- lactamasas
CR20120356A CR20120356A (es) 2002-01-28 2012-06-28 Nuevos compuestos heterocíclicos activos como inhibidores de beta-lactamasas

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20120356A CR20120356A (es) 2002-01-28 2012-06-28 Nuevos compuestos heterocíclicos activos como inhibidores de beta-lactamasas

Country Status (44)

Country Link
US (4) US7612087B2 (cg-RX-API-DMAC7.html)
EP (2) EP2279737B1 (cg-RX-API-DMAC7.html)
JP (1) JP4472346B2 (cg-RX-API-DMAC7.html)
KR (1) KR100979079B1 (cg-RX-API-DMAC7.html)
CN (3) CN101406471A (cg-RX-API-DMAC7.html)
AR (2) AR038234A1 (cg-RX-API-DMAC7.html)
AT (1) ATE484281T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003214335B2 (cg-RX-API-DMAC7.html)
BE (1) BE2016C069I2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0307267B8 (cg-RX-API-DMAC7.html)
CA (1) CA2474043C (cg-RX-API-DMAC7.html)
CL (1) CL2011000009A1 (cg-RX-API-DMAC7.html)
CO (1) CO5601014A2 (cg-RX-API-DMAC7.html)
CR (2) CR7387A (cg-RX-API-DMAC7.html)
CY (3) CY1111061T1 (cg-RX-API-DMAC7.html)
DE (1) DE60334527D1 (cg-RX-API-DMAC7.html)
DK (2) DK2279737T3 (cg-RX-API-DMAC7.html)
EA (1) EA007220B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP045193A (cg-RX-API-DMAC7.html)
ES (2) ES2356813T3 (cg-RX-API-DMAC7.html)
FR (2) FR2835186B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20040686B1 (cg-RX-API-DMAC7.html)
HU (1) HUS1600055I1 (cg-RX-API-DMAC7.html)
IL (1) IL163167A (cg-RX-API-DMAC7.html)
JO (1) JO2646B1 (cg-RX-API-DMAC7.html)
LT (1) LTC1480644I2 (cg-RX-API-DMAC7.html)
MA (1) MA26351A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04006621A (cg-RX-API-DMAC7.html)
MY (1) MY140638A (cg-RX-API-DMAC7.html)
NL (1) NL300847I2 (cg-RX-API-DMAC7.html)
NO (3) NO335195B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ533936A (cg-RX-API-DMAC7.html)
OA (1) OA12761A (cg-RX-API-DMAC7.html)
PE (1) PE20030969A1 (cg-RX-API-DMAC7.html)
PL (1) PL220725B1 (cg-RX-API-DMAC7.html)
PT (2) PT1480644E (cg-RX-API-DMAC7.html)
RS (1) RS52137B (cg-RX-API-DMAC7.html)
SI (2) SI1480644T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN04137A1 (cg-RX-API-DMAC7.html)
TW (1) TWI293071B (cg-RX-API-DMAC7.html)
UA (1) UA80271C2 (cg-RX-API-DMAC7.html)
UY (1) UY27626A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003063864A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200405607B (cg-RX-API-DMAC7.html)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
CN103724330B (zh) 2005-12-07 2015-08-19 巴斯利尔药物股份公司 单环-内酰胺类抗生素与β-内酰胺酶抑制剂的有效的联合应用
EP2040698A4 (en) * 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
EP2078027A1 (en) * 2006-10-23 2009-07-15 Irm Llc Cathepsin proteases inhibitors
US8563732B2 (en) * 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
WO2009114921A1 (en) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
WO2009151152A1 (en) * 2008-06-11 2009-12-17 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
HUE048859T2 (hu) 2010-08-10 2020-08-28 Rempex Pharmaceuticals Inc Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk
CN103328476B (zh) * 2010-12-22 2016-12-28 明治制果药业株式会社 光学活性二氮杂环辛烷衍生物及其制备方法
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
JP6023800B2 (ja) * 2011-06-17 2016-11-09 アストラゼネカ アクチボラグ ｔｒａｎｓ−７−オキソ−６−（スルホオキシ）−１，６−ジアザビシクロ［３，２，１］オクタン−２−カルボキサミドとその塩が含まれる複素環式化合物を製造するための方法
CA2833241C (en) * 2011-08-27 2015-05-12 Wockhardt Limited 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8754102B2 (en) * 2011-09-13 2014-06-17 Wockhardt Ltd. Nitrogen containing compounds and their use
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
US8933233B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MY174523A (en) 2012-05-30 2020-04-23 Meiji Seika Pharma Co Ltd ?-lactamase inhibitor and process for preparing the same
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CA2881169C (en) * 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
AU2014204046B2 (en) 2013-01-04 2017-02-23 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201591003A1 (ru) 2013-01-04 2015-12-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
MY193210A (en) 2013-09-24 2022-09-26 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015053297A1 (ja) 2013-10-08 2015-04-16 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の結晶とその製造法
JP2017506240A (ja) * 2014-02-20 2017-03-02 ウォックハート リミテッド 抗菌剤を含む医薬組成物
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
PT3140310T (pt) 2014-05-05 2019-11-18 Rempex Pharmaceuticals Inc Síntese de sais de boronato e utilizações dos mesmos
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112016026291A2 (pt) 2014-05-19 2017-08-15 Rempex Pharmaceuticals Inc Derivados do ácido borônico e usos terapêuticos dos mesmos
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
MX2016016666A (es) 2014-07-01 2017-08-08 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
TWI690317B (zh) * 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2821826T3 (es) 2014-12-05 2021-04-27 Meiji Seika Pharma Co Ltd Método para producir cristales de derivado de diazabiciclooctano y preparación liofilizada estable
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2983674A1 (en) * 2015-05-07 2016-11-10 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
JP2018515481A (ja) * 2015-09-16 2018-06-14 シュアンチュー ファーマ カンパニー，リミティド β−ラクタマーゼ阻害剤とその利用
AU2016332964A1 (en) 2015-10-02 2018-04-12 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
SG11201811549UA (en) 2016-06-30 2019-01-30 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
PT3512851T (pt) 2016-09-16 2022-10-11 Entasis Therapeutics Ltd Compostos inibidores de beta-lactamase
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
AU2018216243A1 (en) 2017-02-06 2019-08-22 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
SMT202200110T1 (it) 2017-05-08 2022-05-12 Entasis Therapeutics Inc Composti e metodi per trattare infezioni batteriche
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
CN111212843B (zh) 2017-10-11 2025-05-16 Qpex生物制药有限公司 硼酸衍生物及其合成
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
JP7329260B2 (ja) 2018-04-20 2023-08-18 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
FI3833665T3 (fi) 2018-08-09 2023-10-09 Antabio Sas Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
WO2022047603A1 (en) 2020-09-01 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
WO2022233181A1 (en) 2021-05-07 2022-11-10 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
WO1990015058A1 (en) 1989-06-09 1990-12-13 The Upjohn Company Heterocyclic amines having central nervous system activity
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
PT1227103E (pt) 1993-09-29 2006-12-29 Univ Maryland Nucleótidos de anel expandido
WO1995018129A1 (en) * 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
ES2205072T3 (es) * 1996-01-03 2004-05-01 Smithkline Beecham Plc Derivados carbamoiloxi de mutilina y su uso como agentes antibacterianos.
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
US6329389B1 (en) 1998-04-08 2001-12-11 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
EP1091944A1 (en) 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
BR9916328A (pt) 1998-12-18 2001-10-02 Schering Corp Inibidores de transferase de farnesila
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
WO2001025228A1 (en) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Amine derivatives
US20030105118A1 (en) 2000-04-18 2003-06-05 Shuji Masumoto Tricyclic quinazolinediones
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
DE60220057T2 (de) 2001-02-22 2008-01-10 School Of Pharmacy, University Of London Indoline und Tetrahydrochinoline als Prodrugs zur Tumorbehandlung
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
CN1994301A (zh) 2007-07-11
IL163167A (en) 2010-04-15
AU2003214335B2 (en) 2007-04-05
CY2016042I2 (el) 2017-03-15
OA12761A (fr) 2006-07-04
TNSN04137A1 (fr) 2007-03-12
BR0307267A (pt) 2004-12-07
PL220725B1 (pl) 2015-12-31
CN1655781A (zh) 2005-08-17
NO20043587L (no) 2004-08-27
CA2474043A1 (fr) 2003-08-07
CN100482225C (zh) 2009-04-29
AR100790A2 (es) 2016-11-02
ECSP045193A (es) 2004-08-27
KR100979079B1 (ko) 2010-08-31
LTPA2016037I1 (lt) 2017-01-10
ES2356813T3 (es) 2011-04-13
NO335195B1 (no) 2014-10-20
NO2016024I2 (no) 2016-12-15
CY2016042I1 (el) 2017-03-15
MXPA04006621A (es) 2004-10-04
CL2011000009A1 (es) 2011-03-25
LTC1480644I2 (lt) 2018-09-10
CY1111061T1 (el) 2015-06-11
UY27626A1 (es) 2003-08-29
FR16C1019I2 (fr) 2017-12-29
BRPI0307267B8 (pt) 2021-05-25
NO2025027I1 (no) 2025-06-13
NZ533936A (en) 2007-05-31
CO5601014A2 (es) 2006-01-31
FR16C1019I1 (fr) 2017-02-03
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
US20090215747A1 (en) 2009-08-27
PT1480644E (pt) 2011-01-17
DK1480644T3 (da) 2011-01-24
EP2279737A1 (fr) 2011-02-02
DK2279737T3 (da) 2013-02-11
PT2279737E (pt) 2013-02-01
US20100048528A1 (en) 2010-02-25
US20050020572A1 (en) 2005-01-27
HUS1600055I1 (hu) 2017-01-30
HK1105864A1 (zh) 2008-02-29
KR20040081473A (ko) 2004-09-21
EA007220B1 (ru) 2006-08-25
WO2003063864A2 (fr) 2003-08-07
WO2003063864A3 (fr) 2004-03-11
EP1480644B1 (fr) 2010-10-13
MY140638A (en) 2010-01-15
UA80271C2 (uk) 2007-09-10
SI2279737T1 (sl) 2013-07-31
FR2835186B1 (fr) 2006-10-20
HRP20040686A2 (en) 2004-12-31
JP4472346B2 (ja) 2010-06-02
US7612087B2 (en) 2009-11-03
FR2835186A1 (fr) 2003-08-01
HK1077205A1 (zh) 2006-02-10
TWI293071B (en) 2008-02-01
CA2474043C (fr) 2011-08-02
AR038234A1 (es) 2005-01-05
CY1114417T1 (el) 2016-08-31
CN101406471A (zh) 2009-04-15
EP2279737B1 (fr) 2012-10-31
EA200400981A1 (ru) 2005-02-24
SI1480644T1 (sl) 2011-03-31
RS52137B (sr) 2012-08-31
DE60334527D1 (de) 2010-11-25
NO2016024I1 (no) 2016-12-15
HRP20040686B1 (hr) 2013-02-28
YU65804A (sh) 2006-08-17
JO2646B1 (en) 2012-06-17
ES2401855T3 (es) 2013-04-25
MA26351A1 (fr) 2004-10-01
JP2005523897A (ja) 2005-08-11
BE2016C069I2 (cg-RX-API-DMAC7.html) 2022-05-17
NL300847I2 (cg-RX-API-DMAC7.html) 2017-01-03
ATE484281T1 (de) 2010-10-15
CN100563653C (zh) 2009-12-02
PL371601A1 (pl) 2005-06-27
US20110245254A1 (en) 2011-10-06
CR20120356A (es) 2012-10-05
EP1480644A2 (fr) 2004-12-01
ZA200405607B (en) 2005-09-28
BRPI0307267B1 (pt) 2016-02-10

Similar Documents

Publication Publication Date Title
CR7387A (es) Nuevos compuestos heterociclicos activos como inhibidores de las beta- lactamasas
CR10858A (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
PA8527001A1 (es) Poliarilcarboxamidas utiles como agentes reductores de lipidos
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
EA200600925A1 (ru) Производные триазола в качестве антагонистов вазопрессина
PA8496301A1 (es) Inhibidores de metaloproteasas.
NO20051260L (no) Arylsubstituerte diazabicykloalkaner som nikotinacetylcholinagonister
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
SV1999000009A (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol ref. pg3388/sv
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
ES2173846T3 (es) Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2.
AR008861A1 (es) COMPUESTOS DE LACTAMA E IMIDA HETEROCICLICOS DE ARALQUILO Y ARALQUILEDENO, COMPUESTOS INTERMEDIARIOS PARA SU SíNTESIS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN.
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
ECSP055729A (es) Nuevos inhibidores biciclicos de la lipasa sensible a hormonas
CL2011000784A1 (es) Compuestos derivados de 7-h-pirazoli[3,4-e]-diasepina-6(5h)-ona sustituidos; procedimiento de preparacion; composicion farmaceutica, utiles como agentes antibacteriales.
CR10603A (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
SV2003001099A (es) Nuevos derivados de acido sulfonico ref.pc23084
UY27452A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
CR9058A (es) Derivados de indol como inhibidores de la adenilato ciclasa soluble
UY27896A1 (es) Nuevos derivados de piperidina
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis
ECSP066931A (es) Nuevos imidazoles
PA8557201A1 (es) Compuestos basicos lineales que tienen actividad antagonista de nk-2 y su formulaciones
AR002749A1 (es) Derivados de estiril bencimidazol y composicion farmaceutica que los comprende.
CR20150080A (es) Derivados y analogos de n-etilquinolonas y n-etilazaquinolonas